Literature DB >> 1425730

Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40.

J Verhoef1, G Gekker, A Erice, P K Peterson, H H Balfour.   

Abstract

A quantitative coculture assay is described for determining susceptibility of HIV-1 isolates to zidovudine and sCD4 (178)-PE40 (a 60 kDa hybrid protein consisting of the gp120 binding region of CD4 linked to the translocation and ADP-ribosylation regions of Pseudomonas aeruginosa exotoxin). The assay was relatively simple to perform and gave highly reproducible results often within three to five days. IC50 values of zidovudine for HIV-1 strains isolated from two AIDS patients and an asymptomatic seropositive individual were in the range 0.001-0.002 mumol. Isolates obtained after six months of zidovudine treatment had zidovudine IC50 values of 0.01-0.5 mumol. All isolates were equally sensitive to sCD4 (178)-PE40 (IC50 1-5 micrograms/ml). HIV-1 activation in the chronically infected cell line U-1 was inhibited by sCD4 (178)-PE40 but not by zidovudine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425730     DOI: 10.1007/bf01989976

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.

Authors:  R Rooke; M Tremblay; M A Wainberg
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

Review 2.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

3.  Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.

Authors:  T M Folks; S W Kessler; J M Orenstein; J S Justement; E S Jaffe; A S Fauci
Journal:  Science       Date:  1988-11-11       Impact factor: 47.728

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus.

Authors:  Y Hamamoto; H Nakashima; T Matsui; A Matsuda; T Ueda; N Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

6.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.

Authors:  G Poli; J M Orenstein; A Kinter; T M Folks; A S Fauci
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

Review 7.  Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.

Authors:  D D Richman
Journal:  Am J Med       Date:  1990-05-21       Impact factor: 4.965

8.  Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals.

Authors:  J B Jackson; S Y Kwok; J J Sninsky; J S Hopsicker; K J Sannerud; F S Rhame; K Henry; M Simpson; H H Balfour
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.

Authors:  K Gelmon; J S Montaner; M Fanning; J R Smith; J Falutz; C Tsoukas; J Gill; G Wells; M O'Shaughnessy; M Wainberg
Journal:  AIDS       Date:  1989-09       Impact factor: 4.177

View more
  4 in total

1.  Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures.

Authors:  P K Peterson; G Gekker; S Hu; C C Chao
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

2.  kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.

Authors:  C C Chao; G Gekker; S Hu; W S Sheng; K B Shark; D F Bu; S Archer; J M Bidlack; P K Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

Review 4.  Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

Authors:  E A Berger; B Moss; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.